Study Details

Back to Search Results

Comparison of Standard versus Low Dose Advagraf® With or Without angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on Histology and Function of Renal Allografts

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00933231

Astellas Study ID

The unique identification code given by the study sponsor.

FKC-014

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Kidney Transplants

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2009 - Apr 2018

Masking

None (Open Label)

Enrollment number

281

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® with IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Comparison of Standard versus Low Dose Advagraf® With or Without angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on Histology and Function of Renal Allografts? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CA238 Hôpital Maisonneuve-Rosemont

Montreal, Canada, H1T 2M4

Site CA150 St. Joseph's Healthcare

Hamilton, Canada, L8N 4A6

Site CA141 Health Sciences Centre

Winnipeg, Canada, R3A 1R9

Site CA142 St. Paul's Hospital

Saskatoon, Canada, S7V 0Z9

Site CA172 Hôpital Notre-Dame du CHUM

Montreal, Canada, H2L 4M1

Site CA144 McGill University Health Centre

Montreal, Canada, H4A 3J1

Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec

Quebec, Canada, G1R 2J6

Site CA133 Foothills Medical Centre

Calgary, Canada, T2N 2T9

Site CA54 University of Alberta Hospital

Edmonton, Canada, T6G 2B7

Site CA27 London Health Sciences Centre

London, Canada, N6A 5A5

Site CA165 St. Michael's Hospital

Toronto, Canada, M5C 2T2

Site CA114 Capital District Health Authority- QEII Health Sciences Centre

Halifax, Canada, B3H 1V7

Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont

Sherbrooke, Canada, J1H 5N4

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo